Artikel
Depicting the role of the FT functional domains in antiprion mediated neurodegeneration
Suche in Medline nach
Autoren
Veröffentlicht: | 14. September 2016 |
---|
Gliederung
Text
Neurodegeneration is one of the central pathological hallmarks of fatal transmissible spongiform encephalopathy (TSE) affecting humans and animals. Prions represent the causative infectious agent in TSE, which are associated with PrPSC, a pathological conformer of the cellular prion protein (PrPC). The expression of the normal ubiquitously expressed PrPC is a prerequisite for prion induced neurodegeneration [1], [2] and for the propagation of PrPSC [3], [4]. Therefore, one of the first-line targets towards the development of a curative treatment is PrPC, which is encoded by Prnp and contains a globular domain (GD) hinged to an amino-proximal tail (FT, amino-acids 23-125) [5]. Neurotoxicity induced by antiprion antibodies triggers converging pathways as in bona fide TSE [6] and enables the identification of the FT as the mediator of neurotoxicity [7]. In order to identify well-defined therapeutic targets, we now address the relation between the known functional domains of the FT and its pathological function.
In order to investigate the role of FT’s different functional domains in the mediation of neurotoxicity, we assembled AAV with a bicistronic constructs allowing for the expression of unaltered or differently selectively point-mutated PrPC in cerebellar organotypic slice culture (COCS, Figure 1 [Fig. 1]). While PrP deficient mice (PrnpZH3/ZH3) are resistant towards antiprion antibody mediated neurotoxicity, we could monitor a loss of NeonGreen over time in Purkinje cells transfected with unaltered PrPC when treated with the neurotoxic FabPOM19 (Figure 2 A,B [Fig. 2]). This effect was blocked when FabPOM19 was pre-incubated with molar excesses of its cognate antigen. In line with our previous study, antibody mediated neurotoxicity is not restored in PrnpZH3/ZH3 COCS if the deletion mutant PrPΔ32-93 is expressed, which lacks larger part of the aminoterminus including the octarepeat region [7]. In contrast, a restoration was found in all mutants tested to date, which harbored point mutations in either the octarepeat or the SH3 domain (Figure 2C [Fig. 2]).
References
- 1.
- Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 1996 Jan 25;379(6563):339-43.
- 2.
- Mallucci G, Dickinson A, Linehan J, Klöhn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003 Oct 31;302(5646):871-4.
- 3.
- Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell. 1993 Jul 2;73(7):1339-47.
- 4.
- Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev. 2009 Oct;89(4):1105-52. DOI: 10.1152/physrev.00006.2009
- 5.
- Riek R, Hornemann S, Wider G, Glockshuber R, Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett. 1997 Aug 18;413(2):282-8.
- 6.
- Herrmann US, Sonati T, Falsig J, Reimann RR, Dametto P, O'Connor T, Li B, Lau A, Hornemann S, Sorce S, Wagner U, Sanoudou D, Aguzzi A. Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways. PLoS Pathog. 2015 Feb 24;11(2):e1004662. DOI: 10.1371/journal.ppat.1004662
- 7.
- Sonati T, Reimann RR, Falsig J, Baral PK, O'Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, Swayampakula M, Rahman MH, Das D, Kav N, Riek R, Liberski PP, James MN, Aguzzi A. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature. 2013 Sep 5;501(7465):102-6. DOI: 10.1038/nature12402